Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa

Journal of Acquired Immune Deficiency Syndromes

Volumn 58, Issue 3, 2011, Pages 304-308

  Dlamini, J Nomthandazo ^a   Hu, Zonghui ^b   Ledwaba, Johanna ^c   Morris, Lynn ^d   Maldarelli, Frank M ^e   Dewar, Robin L ^e   Highbarger, Helene C ^f   Somaroo, Harsha ^g   Sangweni, Phumelele ^b   Follmann, Dean A ^b   Pau, Alice K ^b  

^a Project Phidisa   (South Africa)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^d NATIONAL CANCER INSTITUTE   (United States)

^e SAIC FREDERICK INC   (United States)

^f 2 Military Hospital   (South Africa)

^g Project Phidisa   (South Africa)

Author keywords

antiretroviral na ve; genotypic resistance; HIV; nonnucleoside reverse transcriptase inhibitors; protease inhibitors; South Africa

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE PLUS STAVUDINE; LOPINAVIR PLUS RITONAVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC RESISTANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REBOUND; SOUTH AFRICA;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HUMANS; LOPINAVIR; MALE; MUTATION; RITONAVIR; RNA, VIRAL; SOUTH AFRICA; TREATMENT FAILURE; VIRAL LOAD;

EID: 80054943288     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182278c29     Document Type: Article

References (19)

1. National Department of Health SA. National Antiretroviral Treatment Guidelines. Pretoria, South Africa: Jacana; 2004:1-93.
2. Department of Health RSA. The South African Antiretroviral Treatment Guidelines. Pretoria, South Africa: Department of Health RSA; 2010: 1-8.
3. Barth RE, Wensing AM, Tempelman HA, et al. Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa. AIDS. 2008; 22:2210-2212.
4. El-Khatib Z, Ekstrom AM, Ledwaba J, et al. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS. 2010;24:1679-1687.
5. Hoffmann CJ, Charalambous S, Sim J, et al. Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis. 2009;49:1928-1935.
6. Wallis CL, Mellors JW, Venter WD, et al. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010;53:480-484.
7. Marconi VC, Sunpath H, Lu Z, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis. 2008;46: 1589-1597. (Pubitemid 351706742)
8. Pillay V, Pillay C, Kantor R, et al. HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. AIDS Res Hum Retroviruses. 2008;24:1449-1454.
9. Orrell C, Walensky RP, Losina E, et al. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther. 2009; 14:523-531.
10. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2011. Available at: http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Accessed February 8, 2011.
11. Hirsch MS, Gunthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis. 2008;47: 266-285. (Pubitemid 351920631)
12. Ratsela A, Polis M, Dhlomo S, et al. A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count ,200 cells/mL in South Africa. J Infect Dis. 2010;202:1529-1537.
13. Pillay V, Ledwaba J, Hunt G, et al. Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther. 2008;13(suppl 2): 101-107. (Pubitemid 352019096)
14. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med. 2009;17: 138-145.
15. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis. 2006;42:1608-1618.
16. Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: highlevel nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS. 2009;23: 1127-1134.
17. Delviks-Frankenberry KA, Nikolenko GN, Boyer PL, et al. HIV-1 reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excision. Proc Natl Acad Sci USA. 2008; 105:10943-10948.
18. Lihana RW, Khamadi SA, Lubano K, et al. HIV type 1 subtype diversity and drug resistance among HIV type 1-infected Kenyan patients initiating antiretroviral therapy. AIDS Res Hum Retroviruses. 2009;25: 1211-1217.
19. Price MA, Wallis CL, Lakhi S, et al. Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retroviruses. 2011;27:5-12.